Bortezomib for Injection Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Bortezomib for Injection, 3.5 mg per vial in a 10 mL single-dose vial.

Meitheal will offer Bortezomib for Injection in a carton of 1 vial.


Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma. For full prescribing information and safety information, please click on the following link.

Learn more about Bortezomib for Injection.

This Website Uses Cookies

This website uses cookies to help us give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can read more about our use of cookies in our Privacy Policy.

Accept cookies Reject cookies